The H. Lee Moffitt Cancer Center in Tampa, FL, has inked a license agreement with CvergenX, Inc., for the exclusive worldwide rights to a technology platform called InterveneXRT that individualizes radiation therapy. Moffitt researchers have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors. “While genomic analysis has been applied in the development of diagnostic tools to guide chemotherapy use, this is the first time that the field has expanded to radiation therapy,” says Javier F. Torres-Roca, MD, a radiation oncologist who co-founded CvergenX with fellow Moffitt faculty member Steven A. Eschrich, PhD. “This level of analysis will truly individualize each treatment, arming oncologists with answers as to when and how much to radiate.” Radiation therapy is prescribed for more than 60% of cancer patients, according to the company.

The testing platform is undergoing clinical studies for further validation and optimization of its methods. Under the license agreement, CvergenX has agreed to make payments to Moffitt when various commercialization milestones are reached and to make royalty payments on the sales of testing services and licensed products. “The license agreement is one of the key milestones established for the company in 2010,” says Mary Del Brady, chairman and CEO of CvergenX. “With the intellectual property fully protected, we are poised to proceed with the commercialization of InterveneXRT.”

Source:  PR Newswire

Posted August 4th, 2010 under Tech Transfer

Write a comment